Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP

European Journal of Haematology

Volumn 68, Issue 3, 2002, Pages 135-143

  Economopoulos, T ^a,h   Dimopoulos, M A ^b   Mellou, S ^a   Pavlidis, N ^c   Samantas, E ^d   Nicolaides, C ^c   Tsatalas, C ^e   Papadopoulos, A ^f   Papageogriou, E ^a   Papasavvas, P ^g   Fountzilas, G ^f  

^a UNIVERSITY OF ATHENS   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

^d Cancer Hospital   (Greece)

^e DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^f ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^g IASO GENERAL HOSPITAL   (Greece)

^h EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Aggressive non Hodgkin's lymphoma; CEOP; CNOP

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; EPIRUBICIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MITOXANTRONE; NEUTROPENIA; PREDNISOLONE; PREDNISONE; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 0036270309     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.01620.x     Document Type: Article

References (26)

1. Comparison of a second generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma
2. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
3. Phase I-II trial of high-dose epirubicin in patients with lymphoma
4. Chemotherapy of intermediate and high-grade non-Hodgkin's lymphomas with an intensive epirubicin-containing regimen
5. Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease
6. Results of a randomized study of previously untreated intermediate and high grade lymphoma using CHOP versus CNOP
7. A phase III comparative trial of m-BACOD vs. m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin's lymphomas
8. Long-term results of a multicenter randomized comparative phase II trial of CHOP versus CNOP regimens in patients with intermediate and high grade non-Hodgkin's lymphomas
9. Elderly aggressive non-Hodgkin's lymphoma: First line VNCOP-B regimen experience on 350 patients
10. National cancer institute sponsored study of classification of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage
11. Report of the Committee on Hodgkin's disease staging classification
12. A predictive model for aggressive non-Hodgkin's lymphoma
13. Exact significance testing to establish treatment equivalence for ordered categorical data
14. Non-parametric estimation from incomplete observations
15. Asymptotically efficient rank invariant test procedures
16. Regression models and life tables
17. Artial residuals for the proportional hazards regression models
18. Martingale based residuals' for survival models
19. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high-dose methotrexate alternating with standard agents (M-BACOD)
20. Infusional combination chemotherapy for diffuse large cell lymphoma
21. Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of Pro-MACE and MOPP chemotherapy
22. Combination chemotherapy including epirubicin for the management of non-Hodgkin's lymphoma
23. A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma
24. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy